Loading...
Opening the door to follow-on proteins?
When the FDA approved the follow-on protein Omnitrope in May, it gave generic drug makers the wedge they were hoping for. With pressure building in Washington, did Omnitrope push the door open – or was it just an anomaly?
Na minha lista:
| Hovedforfatter: | |
|---|---|
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
BioCommunications LLC
2006
|
| Fag: | |
| Online adgang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3571050/ https://ncbi.nlm.nih.gov/pubmed/23424385 |
| Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|